Whether some of the novel oncocytic and molecularly defined RCC subtypes (eosinophilic vacuolated tumour, low-grade oncocytic tumour and TFE3-rearranged, TFEB-altered, ELOC (formerly TCEB1)-mutated, fumarate hydratase-deficient, succinate dehydrogenase-deficient, ALK-rearranged renal cell carcinomas and SMARCB1-deficient renal medullary carcinoma)—which were not distinguished in our historic tumor collection—may be particularly linked to CDH16 negativity needs to be determined in further studies. This evidence concerns the gene SMARCB1 and hereditary clear cell renal cell carcinoma.